Vernalis And Servier Join Forces To Develop Oncology Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Servier was attracted to Vernalis based on the firm’s development work with Novartis on another oncology compound, Vernalis CEO tells “The Pink Sheet” DAILY.